When is it too EARLY to start bosentan in pulmonary arterial hypertension?

Magdy, F.
October 2008
Thorax;Oct2008, Vol. 63 Issue 10, p865
Academic Journal
The article reports the therapeutic use of bosentan (dual endothelin receptor antagonist) in pulmonary arterial hypertension, which is presented under the EARLY trial study. It defines pulmonary arterial hypertension as a debilitating progressive disease that leads to right heart failure and death. An overview of the conducted research is offered. It shows with the use of bosentan there is an improvement in hemodynamics and prevention of clinical deterioration.


Related Articles

  • Pressure-overload-induced right heart failure. Rain, S.; Handoko, M.; Vonk Noordegraaf, A.; Bogaard, H.; Velden, J.; Man, F. // Pflugers Archiv European Journal of Physiology;Jun2014, Vol. 466 Issue 6, p1055 

    Although pulmonary arterial hypertension originates in the lung and is caused by progressive remodeling of the small pulmonary arterioles, patients die from the consequences of pressure-overload-induced right heart failure. Prognosis is poor, and currently there are no selective treatments...

  • Current Pharmacological Treatment of Pulmonary Arterial Hypertension. Steiropoulos, Paschalis; Trakada, Georgia; Bouros, Demosthenes // Current Clinical Pharmacology;Jan2008, Vol. 3 Issue 1, p11 

    Pulmonary arterial hypertension (PAH) is a disease characterized by an elevation in pulmonary artery pressure that can lead to right ventricular failure and death. Conventional treatment is based on non-specific drugs (warfarin, oxygen, diuretics). Pure vasodilators like calcium channel...

  • Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Valerio, Christopher J.; Handler, Clive E.; Kabunga, Peter; Smith, Colette J.; Denton, Christopher P.; Coghlan, John G. // Rheumatology;Nov2010, Vol. 49 Issue 11, p2147 

    Objectives. To report outcomes in patients with CTD-pulmonary arterial hypertension (CTD-PAH) in an observational cohort treated with bosentan or sitaxentan and determine whether differences would justify a randomized, controlled multicentre study in this subpopulation.Methods. Patients with...

  • New drug considered better way to treat pulmonary hypertension.  // Drug Topics;1/7/2002, Vol. 146 Issue 1, p20 

    Reports on the approval of an oral pill developed by Actelion USA for the treatment of pulmonary arterial hypertension in January 2002. Information on the disease; Mechanism of action of the drug. INSET: TIPS TO REMEMBER.

  • New way to treat pulmonary hypertension?  // Journal of Clinical Investigation;Jul2011, Vol. 121 Issue 7, p2529 

    An introduction to the journal is presented in which the editor provides new insight to treat pulmonary arterial hypertension (PAH).

  • Pulmonary Arterial Hypertension: Epidemiology and Registries. McGoon, Michael D.; Humbert, Marc // Advances in Pulmonary Hypertension;2014, Vol. 13 Issue 1, p21 

    Registries of pulmonary arterial hypertension (PAH) are important means by which to characterize the presentation and outcome of patients and to provide a basis for predicting the course of the disease. This article summarizes the published conclusions of the World Symposium of Pulmonary...

  • Cost-Utility of Treatments for Pulmonary Arterial Hypertension. Garin, Margaret C.; Clark, Leslie; Chumney, Elinor C. G.; Simpson, Kit N.; Highland, Kristin B. // Clinical Drug Investigation;2009, Vol. 29 Issue 10, p635 

    Background and Objective: Clinicians must choose between an increasing number of medications for the treatment of pulmonary arterial hypertension (PAH) with different routes of administration, adverse effects, costs and efficacies. We constructed a decision analysis to help inform treatment...

  • Bad News, Good News for United's Oral PAH Program. Boggs, Jennifer // BioWorld Today;11/18/2008, Vol. 19 Issue 225, p1 

    The article discusses the dosing issues of an oral pulmonary arterial hypertension (PAH) drug formulated by United Therapeutics Corp., a firm based in Silver Spring, Maryland and its impact on the company's shares. It states that the firm's shares sank 35% when the drug known as tresprostinil...

  • Classification of Pulmonary Hypertension. Souza, Rogerio; Simonneau, Gerald // Advances in Pulmonary Hypertension;2014, Vol. 13 Issue 1, p17 

    Classification of pulmonary hypertension groups patients with similar pathological findings, hemodynamic profiles, and management strategies. Minor modifications have been made to the current classification system, particularly within Group 1 pulmonary arterial hypertension. This article...


Read the Article


Sign out of this library

Other Topics